ロード中...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science (PLoS)
2018-01-01
|
| シリーズ: | PLoS ONE |
| オンライン･アクセス: | http://europepmc.org/articles/PMC5976165?pdf=render |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|